Neil Cohen | Chief Executive Officer

Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com (Nasdaq: SHOP, acquired by EBAY), Broadlight (acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private equity firm, at Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at the Rothschild Bioscience Unit of N M Rothschild & Sons Limited in London. Mr. Cohen received a B.A. and M.A., with first class honors, from Oxford University.

Andrew Fine | Chief Financial Officer

Mr. Fine has served as our Chief Financial Officer since July 2020. Mr. Fine has over 20 years of experience in executive financial and operational roles and is currently Co-Managing Director at Line Consulting Ltd. Mr. Fine previously held roles as Chief Financial Officer at Seeking Alpha, ScaleMP and Freightos , leading finance and operations for the companies’ global activities.  Mr. Fine holds a BA and an MBA from the Hebrew University of Jerusalem.

Salar Roshan | Vice President, Head of Business Development

Mr. Roshan has served as our Head of Business Development since May 2019. Mr. Roshan leads the development of strategic partnerships and spearheaded the licensing transaction surrounding our pan-RAS and PDE10/β-catenin programs. Mr. Roshan joined Anchiano Therapeutics from Curis, Inc., an anti-cancer biotechnology company, where he served as Head of Corporate Development and was responsible for overseeing all aspects of the company’s corporate and business development strategy. Prior to that, he led the partial spin-off of the R&D division of Baxter Biosciences into Baxalta. While at Baxalta, he was also responsible for several product launches and oversaw valuation and long range planning for the hemophilia portfolio, which grossed roughly $4 billion in annual sales prior to Baxalta’s merger with Shire PLC. Mr. Roshan has also held roles of increasing responsibility at Ironwood Pharmaceuticals, Takeda US, Millennium Pharmaceuticals, and Genzyme. Mr. Roshan received his M.Sc. in finance and his M.B.A. from Kelley School of Business at Indiana University, and his B.Sc. in biotechnology from Northeastern University.